Citigroup
HRTX icon

Citigroup’s Heron Therapeutics HRTX Stock Holding History

Citigroup’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,800
Closed -$21K – 7594
2020
Q1 		$21K Sell
1,800
-18,600
-91% -$350K ﹤0.01% 6657
2019
Q4 		$479K Sell
20,400
-5,000
-20% -$111K ﹤0.01% 4452
2019
Q3 		$470K Buy
25,400
+6,100
+32% +$112K ﹤0.01% 4396
2019
Q2 		$359K Buy
19,300
+7,000
+57% +$140K ﹤0.01% 4754
2019
Q1 		$301K Buy
12,300
+9,500
+339% +$249K ﹤0.01% 4700
2018
Q4 		$73K Sell
2,800
-16,200
-85% -$445K ﹤0.01% 5916
2018
Q3 		$601K Sell
19,000
-300
-2% -$11.2K ﹤0.01% 4062
2018
Q2 		$750K Buy
19,300
+500
+3% +$15.9K ﹤0.01% 3667
2018
Q1 		$519K Sell
18,800
-44,100
-70% -$1M ﹤0.01% 3951
2017
Q4 		$1.14M Buy
62,900
+23,600
+60% +$385K ﹤0.01% 3212
2017
Q3 		$635K Buy
39,300
+28,300
+257% +$444K ﹤0.01% 3854
2017
Q2 		$152K Buy
11,000
+500
+5% +$7.24K ﹤0.01% 5016
2017
Q1 		$158K Buy
10,500
+8,500
+425% +$118K ﹤0.01% 4853
2016
Q4 		$26K Sell
2,000
-5,700
-74% -$89.4K ﹤0.01% 6422
2016
Q3 		$133K Sell
7,700
-4,300
-36% -$79.8K ﹤0.01% 5000
2016
Q2 		$217K Sell
12,000
-2,900
-19% -$56.6K ﹤0.01% 4420
2016
Q1 		$283K Buy
14,900
+5,500
+59% +$109K ﹤0.01% 4751
2015
Q4 		$251K Sell
9,400
-59,200
-86% -$1.58M ﹤0.01% 4530
2015
Q3 		$1.67M Buy
+68,600
New +$2.29M ﹤0.01% 2619

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Citigroup's HRTX Position: Q1 2026 in Review

Citigroup increased its Heron Therapeutics (HRTX) stake by 108% in Q1 2026, buying an estimated $4.36K and bringing the position to 7,240 shares worth $5.79K. The position accounts for ﹤0.01% of the portfolio, ranked #5223.

Citigroup first reported a position in HRTX in Q1 2014 and has held it in 49 quarters since. The position peaked at $14.9M in Q2 2017. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Citigroup held 7,240 shares of Heron Therapeutics worth $5.79K as of Q1 2026.
  • Citigroup bought 3,762 Heron Therapeutics shares in Q1 2026, an estimated $4.36K.
  • Heron Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5223 holding.
  • Citigroup first reported a position in Heron Therapeutics in Q1 2014 and has held it in 49 quarters since.
  • Citigroup's Heron Therapeutics position peaked at $14.9M in Q2 2017.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.